Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience
Article in Cancers (February 2023)
The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.
Radioresistance in rhabdomyosarcomas: Much more than a question of dose
Article in Frontiers in Oncology (September 2022)
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
Article in Therapeutic Advances in Hematology (January 2022)